#jn1 — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #jn1, aggregated by home.social.
-
conscientious objector🇨🇭🪂 @[email protected] (🇲) Es gibt fast überall #Biontech #NP8. Es gibt aber auch #Novavax #JN1. Zumindest in der #Reisepraxis :syslink: BCRT -
Die Impfung für NP8.1 von Biontech gibt es ja vielerorts. Aber es ist auch eine Impfung gegen JN1 erhältlich mit dem Impfstoff von Novavax in der Reisepraxis BCRT an vielen Orten in Deutschland. In Berlin in der Friedrichstraße sind vermutlich zeitnah keine Termine frei, aber in Steglitz (Globetrotter, obere Etage) ist es ohne Termin möglich.
#Covid #COVID19 #corona #sars #Impfung #biontech #novavax #np8 #np81 #jn1
-
Impfmöglichkeit Booster Auffrischung 💉Grippe #Sanofi #Novavax #Nuvaxovid #JN.1 #Biontech #Comirnaty #L.P.8.1 📆Termine ab 27.11. 🏥Elefanten Apotheke 📍Dörpfeldstr. 46 12489 #Berlin #Adlershof 📞03067894942 📧 [email protected] #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #nuvax25 #impflp81
-
⬆️ Impfmöglichkeit Booster Auffrischung 💉 #Novavax #Nuvaxovid #JN.1 📍 #Aachen #NRW 📆 mit Termin (📞); Termine ab 29.11.25 📞 0241-91993694 🚦Ü12. Stikotreue unklar, gern berichten. @drmccoy.info @safeairdocs.bsky.social @bildungabersicher.net #COVID19 #CovidIsNotOver #TeamVorsicht #Impfung #nuvax25
-
Falls ihr euch fragt, wie sicher die Impfung ist:
Dänische Forscher:innen haben sich die Boosterimpfung aus der Periode 2024/25 angeschaut. Bei mehr als einer Millione geimpfter Personen wurde kein statistisch auffälliger Wert von unerwünschten Ereignissen im Vergleich zur nicht-geimpften Bevölkerung gefunden.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2836889
-
Effectiveness of #BNT162b2 and #mRNA-1273 #JN1-adapted #vaccines against #COVID19-associated #hospitalisation and #death ..., https://etidiohnew.blogspot.com/2025/07/effectiveness-of-bnt162b2-and-mrna-1273.html
-
#Malaysia, #Covid19: Health Ministry urges high-risk groups to get vaccinated amid #JN1 #subvariant spread https://www.malaymail.com/news/malaysia/2025/06/12/covid-19-health-ministry-urges-high-risk-groups-to-get-vaccinated-amid-jn1-subvariant-spread/180121
-
Feverʼs pretty much gone. Inanahi was pretty miserable. Still, better than getting the plague. #COVID19 #JN1 #vaccination
-
Numb arm and fever, but better than getting the actual thing! #COVID19 #JN1 #vaccination
-
-
#XBB.1.5 monovalent #vaccine induces lasting cross-reactive responses to #SARS-CoV-2 #variants such as HV.1 and #JN1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific #antibodies, https://etidiohnew.blogspot.com/2025/03/xbb15-monovalent-vaccine-induces.html
-
Impfaktion am 18.1. 2025 in #berlinmitte
#Comirnaty #JN1 (Alter ab 6 Monate)
und
#Novavax #Nuvaxovid #JN1 (ab 12 Jahren).Kosten: 15€/Impfling.
Für Voranmeldung Mail-Adresse bei uns erfragen.
-
[Correspondence] #Antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against SARS-CoV-2 omicron subvariants including #JN1, #KP311, and #XEC https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00810-7/fulltext?rss=yes
Our data suggest that the receptor-binding domain of JN.1 S can effectively induce antiviral humoral immunity against JN.1 subvariants and XEC comparable to the full-length JN.1 S.
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Gibt es eigentlich Studien darüber,
a) welche Wirkung es genauer hat, wenn man 7, 8, 9 … Mal geimpft ist;
b) welche Wirkung eine Impfung auf den Verlauf hat, wenn man sich zufällig kurz darauf infiziert?
Beide Fragen scheinen eher unbeachtet.
#CovidIsNotOver #ImpfenSchützt #Kontrollgruppe #Corona #jn1 #kp2
-
Robust #antiviral humoral #immunity induced by #JN1 monovalent #mRNA #vaccines against a broad range of #SARS-CoV-2 #Omicron subvariants including #JN1, #KP311 and #XEC
Source: BioRxIV, AbstractAs of November 2024, SARS-CoV-2 Omicron JN.1 subvariants, such as KP.2 (JN.1.11.1.2), KP.3 (JN.1.11.1.3), KP.3.1.1 (JN.1.11.1.3.1.1), and XEC, a recombinant lineage between KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3), have been circulating in several countries. To control…
-
Neutralizing #Activity and Viral #Escape of #Pemivibart by #SARS-CoV-2 #JN1 #sublineages
Source: BioRxIV, AbstractPemivibart (Pemgarda/VYD222) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on March 22, 2024, for COVID-19 pre-exposure prophylaxis in immunocompromised individuals. However, its efficacy and resistance against JN.1 sublineages have yet to be fully characterized. Here, we first assessed the neutralizing…
-
#SARS-CoV-2 #JN1 reveals attenuated #pathogenicity and #airborne #transmission
Source: BioRxIV, AbstractJN.1 is a subvariant of SARS-CoV-2 Omicron BA.2.86 lineage that was predominant worldwide in early 2024, of which the in vivo characteristics are largely unknown. Our results demonstrated that the replication of JN.1 was more efficient than that of the parental BA.2 in Vero cells, which demonstrated low dependence on TMPRSS2. Compared to Omicron variants BA.2 and XBB…
-
Evolving #antibody #response to #SARS-CoV-2 #antigenic #shift from #XBB to #JN1
Source: Nature, AbstractThe continuous evolution of SARS-CoV-2, particularly the emergence of BA.2.86/JN.1 lineage replacing XBB, necessitates re-evaluation of vaccine compositions 1–3. Here, we provide a comprehensive analysis of the humoral immune response to XBB and JN.1 human exposure. We demonstrate the antigenic distinctiveness of XBB and JN.1 lineages in SARS-CoV-2-naive individuals,…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
#Immunologic and Biophysical #Features of the #BNT162b2 #JN1 – and #KP2-Adapted #COVID19 #Vaccines
Source: BioRxIV, AbstractVaccines remain a vital public health tool to reduce the burden of COVID-19. COVID-19 vaccines that are more closely matched to circulating SARS-CoV-2 lineages elicit more potent and relevant immune responses that translate to improved real-world vaccine effectiveness. The rise in prevalence of the Omicron JN.1 lineage, and subsequent derivative…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
Neutralizing #antibody #evasion of #SARS-CoV-2 #JN1 derivatives #KP3, #KP311, #LB1, and #XEC
Source: BioRxIV, AbstractThe emergence of SARS-CoV-2 variants poses ongoing challenges to vaccine efficacy. We evaluated neutralizing antibody responses against JN.1 and its derivatives (KP.3, KP.3.1.1, LB.1, and XEC) in healthcare workers who received seven doses of BNT162b2, including XBB.1.5 monovalent vaccine. In COVID-19-naive individuals, KP.3.1.1 and LB.1 showed…
-
#Lineage-specific #pathogenicity, immune #evasion, and virological #features of #SARS-CoV-2 #BA286 / #JN1 and #EG51 / HK.3
Source: Nature Communications, AbstractSARS-CoV-2 JN.1 with an additional L455S mutation on spike when compared with its parental variant BA.2.86 has outcompeted all earlier variants to become the dominant circulating variant. Recent studies investigated the immune resistance of SARS-CoV-2 JN.1 but additional factors are speculated to contribute to…
-
Structural basis for #receptor-binding domain mobility of the #spike in #SARS-CoV-2 #BA286 and #JN1
Source: Nature Communications, AbstractSince 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the up-conformation. However, whether ACE2 also interacts with the RBD in the down-conformation to…
-
#Impact of #JN1 #booster #vaccination on #neutralisation of #SARS-CoV-2 variants #KP311 and #XEC
Source: BioRxIV, {Excerpt} Conclusion Collectively, we found that the XEC S protein retains the ability to efficiently engage ACE2 and drive cell entry, although entry into Calu-3 lung cells was reduced. Both KP.3.1.1pp and XECpp were generally less well neutralised compared to JN.1pp, indicating elevated immune evasion. Importantly, JN.1-booster vaccination significantly…
-
#Human and #hamster #sera correlate well in identifying #antigenic #drift among #SARS-CoV-2 #variants, including #JN1
Source: Journal of Virology, ABSTRACTAntigenic assessments of SARS-CoV-2 variants inform decisions to update COVID-19 vaccines. Primary infection sera are often used for assessments, but such sera are rare due to population immunity from SARS-CoV-2 infections and COVID-19 vaccinations. Here, we show that neutralization titers and breadth of matched…
-
Immune #escape and attenuated #severity associated with the #SARS-CoV-2 #BA286 / #JN1 #lineage
Source: Nature Communications, AbstractThe SARS-CoV-2 BA.2.86 lineage, and its sublineage JN.1 in particular, achieved widespread transmission in the US during winter 2023–24. However, this surge in infections was not accompanied by COVID-19 hospitalizations and mortality commensurate with prior waves. To understand shifts in COVID-19 epidemiology associated with JN.1…
-
Variants: JN.1 vs KP.2 vs KP.3.1.1
What is the most common COVID-19 variant right now and how does it compare to the JN.1 variant that swept the world almost a year ago? What do the variant designations like KP.3.1.1 mean? How important is just 1 mutation? Can just 1 mutation potentially affect our immunity and how vaccines are designed? Read on to find out answers to this and more. 🧵 1/
-
Diese Praxis in Bremen Nord impft wieder gegen Corona, und zwar auch Nichtpatienten, mit dem JN.1-angepassten Impfstoff von Biontech. Es wird bei der Terminbuchung auf die Stikoks verwiesen. Im Zweifel nachfragen oder einfach versuchen durchzuziehen, je nach Mindset.
https://www.hausarztpraxis-lesumpark.de/impfung-gegen-covid-19/
#CovidIsNotOver #Impfung #Comirnaty #Bremen #Arztpraxis #jn1 #kp3 #Booster
-
Diese Praxis in Bremen Nord impft wieder gegen Corona, und zwar auch Nichtpatienten, mit dem JN.1-angepassten Impfstoff von Biontech. Es wird bei der Terminbuchung auf die Stikoks verwiesen. Im Zweifel nachfragen oder einfach versuchen durchzuziehen, je nach Mindset.
https://www.hausarztpraxis-lesumpark.de/impfung-gegen-covid-19/
#CovidIsNotOver #Impfung #Comirnaty #Bremen #Arztpraxis #jn1 #kp3 #Booster
-
Diese Praxis in Bremen Nord impft wieder gegen Corona, und zwar auch Nichtpatienten, mit dem JN.1-angepassten Impfstoff von Biontech. Es wird bei der Terminbuchung auf die Stikoks verwiesen. Im Zweifel nachfragen oder einfach versuchen durchzuziehen, je nach Mindset.
https://www.hausarztpraxis-lesumpark.de/impfung-gegen-covid-19/
#CovidIsNotOver #Impfung #Comirnaty #Bremen #Arztpraxis #jn1 #kp3 #Booster
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1
We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.
-
Structural and molecular #basis of the #epistasis effect in enhanced affinity between #SARS-CoV-2 #KP3 and #ACE2 http://biorxiv.org/cgi/content/short/2024.09.03.610799v1?rss=1
KP.3, featuring F456L and Q493E, exhibits a markedly enhanced ACE2 binding affinity compared to #KP2 and #JN1 #variant due to synergistic effects between these mutations.
-
Structural and molecular #basis of the #epistasis effect in enhanced affinity between #SARS-CoV-2 #KP3 and #ACE2 http://biorxiv.org/cgi/content/short/2024.09.03.610799v1?rss=1
KP.3, featuring F456L and Q493E, exhibits a markedly enhanced ACE2 binding affinity compared to #KP2 and #JN1 #variant due to synergistic effects between these mutations.
-
Structural and molecular #basis of the #epistasis effect in enhanced affinity between #SARS-CoV-2 #KP3 and #ACE2 http://biorxiv.org/cgi/content/short/2024.09.03.610799v1?rss=1
KP.3, featuring F456L and Q493E, exhibits a markedly enhanced ACE2 binding affinity compared to #KP2 and #JN1 #variant due to synergistic effects between these mutations.